Omnicare recent pullback is overdone, says Credit Suisse Credit Suisse said Omnicare's proposed divestiture of the Hospice/Retail businesses will lower the earnings run-rate but growth is poised to reaccelerate in 2015. Additionally, the analyst said there are several drivers that could drive earnings above consensus that include LTC pharmacy top line organic growth, a strong generic launch backdrop, and healthy growth in the broader specialty market. Shares are Outperform rated with a $68 price target.
News For OCR From The Last 14 Days
Check below for free stories on OCR the last two weeks.